TheEdgeResearch
Home / Stocks / QRON

Qrons Inc. (QRON)

OTC Healthcare Biotechnology
$0.01 ▼ -0.89%
Market Cap
$199,800
Sector
Healthcare
Industry
Biotechnology
Beta
0.86
52-Wk Range
0.0111-0.173
CEO
Cory J. Rosenberg
Country
US
Currency
USD

Qrons Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Glendale, BY, US. The stock last traded at $0.01, down 0.89% on the session, giving a market capitalisation of $199,800. On trailing twelve-month figures it carries a trailing P/E of -2.77, a net margin of 0.0%. Its beta of 0.86 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.77
Price / Sales
0.00
Price / Book
-0.35
EV / EBITDA
-4.31
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.67
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2021-07-14
Headquarters
Glendale, BY, US
About Qrons Inc.

Qrons, Inc. is a biotechnology company, which engages in the development of treatments and technologies for neuronal and infectious diseases. Its proprietary patents include Techniques for Promoting Neuronal Recovery, Therapeutic Polypseudorotaxane Hydrogels, and Tellurium Compositions and Techniques for Use Therewith. The company was founded by Jonah Martin Meer and Ido Merfeld on August 22, 2016 and is headquartered in Glendale, CA.

Comparable companies

Qrons Inc. is most often compared with the following Healthcare names:

AOXGBIOAFBSYICBDLETBIHMGNJUVAFLRSVRGMPRGRX
More research on QRON
QRON technical analysis QRON TheEdge Score Compare against peers
Open full interactive analysis & DCF →